AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25515221 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (three times/week, 30 min, 70% VO(2) max; n = 24)
Number of subjects: 47
Study 25515221 — intervention group
Group type: COMPARATOR
Intervention: Low intensity physical activity (n = 23)
Number of subjects: 47
Study 23533227 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel (2 doses targeting either 400-550 ng/dL or 600-1000 ng/dL)
Number of subjects: 167
Study 23533227 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT)
Number of subjects: 167
Study 23533227 — intervention group
Group type: COMPARATOR
Intervention: No exercise (non-PRT group)
Number of subjects: 167
Study 23533227 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 167
Study 20546622 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-platelet drug use (50% of diabetic patients)
Number of subjects: 1007
Study 20546622 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet inhibitor use (including aspirin and non-aspirin)
Number of subjects: 1007
Study 18811599 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin 7.5 mg once daily (up-titrated to 15 mg after 2 weeks if needed) for up to 12 weeks
Number of subjects: 497
Study 16329997 — intervention group
Group type: EXPERIMENTAL
Intervention: OX40 gene variants (specifically polymorphism in intron 5, rs2298212)
Number of subjects: 0
Study 16329997 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variation (rs2298211) linked to intronic variant
Number of subjects: 0
Study 12542559 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK infusion
Number of subjects: 33
Study 12542559 — intervention group
Group type: COMPARATOR
Intervention: MIT
Number of subjects: 33
Study 10584288 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 0
Study 10584288 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT)
Number of subjects: 0
Study 7755069 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime (2 gm every 8 hours)
Number of subjects: 117
Study 7755069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 2097485 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 20 micrograms (0.4 ml) with 0.5% heavy marcaine 2.0 ml
Number of subjects: 60
Study 2097485 — intervention group
Group type: COMPARATOR
Intervention: Control group: 0.5% heavy marcaine 2.0 ml with CSF 0.4 ml
Number of subjects: 60
Study 2097485 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl group
Number of subjects: 60
Study 2097485 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 6457568 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% solution of erythromycin
Number of subjects: 0
Study 6457568 — intervention group
Group type: COMPARATOR
Intervention: Blank vehicle
Number of subjects: 0
Study 30345963 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia crowns
Number of subjects: 50
Study 30345963 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel crowns (SSCs)
Number of subjects: 50
Study 27119575 — intervention group
Group type: COMPARATOR
Intervention: PD 0348292 (2.5-150 mg)
Number of subjects: 0
Study 27119575 — intervention group
Group type: COMPARATOR
Intervention: PD 0348292 (5-30 mg) every 12 hours
Number of subjects: 0
Study 27119575 — intervention group
Group type: COMPARATOR
Intervention: PD 0348292 (5 mg) single dose
Number of subjects: 0
Study 27119575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27119575 — intervention group
Group type: EXPERIMENTAL
Intervention: PD 0348292
Number of subjects: 0
Study 25056151 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate therapy group receiving physical therapy (maximum of 12 sessions of 30 min for a 6-week program)
Number of subjects: 0
Study 25056151 — intervention group
Group type: COMPARATOR
Intervention: Delayed therapy group (6 weeks delay before starting therapy)
Number of subjects: 0
Study 22033354 — intervention group
Group type: EXPERIMENTAL
Intervention: Quasi-long pulse and Q-switched Nd:YAG laser treatment with topically applied carbon suspension
Number of subjects: 22
Study 20576793 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous for the variant allele of rs12757998 (AA)
Number of subjects: 1286
Study 20576793 — intervention group
Group type: EXPERIMENTAL
Intervention: Missense mutations R462Q and D541E
Number of subjects: 1286
Study 20576793 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1286
Study 18035092 — intervention group
Group type: EXPERIMENTAL
Intervention: HFRC (heart failure patient-specific quality-of-care report cards)
Number of subjects: 265
Study 18035092 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 265
Study 16518704 — intervention group
Group type: EXPERIMENTAL
Intervention: 330GG genotype
Number of subjects: 382
Study 16518704 — intervention group
Group type: EXPERIMENTAL
Intervention: 330TT genotype
Number of subjects: 382
Study 16518704 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of -330G allele frequency
Number of subjects: 382
Study 12390708 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEGF ophthalmic solution
Number of subjects: 36
Study 12390708 — intervention group
Group type: COMPARATOR
Intervention: Drug vehicle (control)
Number of subjects: 36
Study 9702646 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological preparation (demonstration of materials, use of a doll, or a book with photographs)
Number of subjects: 60
Study 9702646 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological preparation
Number of subjects: 60
Study 7737255 — intervention group
Group type: EXPERIMENTAL
Intervention: Castration plus nilutamide
Number of subjects: 270
Study 7737255 — intervention group
Group type: COMPARATOR
Intervention: Casodex (ICI 176,334) monotherapy
Number of subjects: 270
Study 2913777 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 17
Study 2913777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 30617417 — intervention group
Group type: EXPERIMENTAL
Intervention: Water at 2 °C
Number of subjects: 11
Study 30617417 — intervention group
Group type: COMPARATOR
Intervention: Water at 37 °C
Number of subjects: 11
Study 30617417 — intervention group
Group type: COMPARATOR
Intervention: Water at 60 °C
Number of subjects: 11
Study 29650341 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Diversity Score (DDS)
Number of subjects: 300
Study 28222543 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal cerebellar tDCS (2 mA for 10 minutes)
Number of subjects: 14
Study 28222543 — intervention group
Group type: COMPARATOR
Intervention: Cathodal cerebellar tDCS (2 mA for 10 minutes)
Number of subjects: 14
Study 28222543 — intervention group
Group type: COMPARATOR
Intervention: Sham cerebellar tDCS (2 mA for 10 minutes)
Number of subjects: 14
Study 25218922 — intervention group
Group type: EXPERIMENTAL
Intervention: DCCT/EDIC time-weighted hemoglobin A1c
Number of subjects: 639
Study 25218922 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 639
Study 25218922 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-weighted hemoglobin A1c
Number of subjects: 639
Study 23810377 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX-6 combined with bevacizumab and MetMAb
Number of subjects: 0
Study 23810377 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX-6 combined with bevacizumab and placebo
Number of subjects: 0
Study 21487640 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (10 cmH2O for 30 minutes)
Number of subjects: 12
Study 21487640 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study 19466247 — intervention group
Group type: EXPERIMENTAL
Intervention: Duofluorid XII (2.92% fluorine, calcium fluoride + 2.71% fluorine, sodium fluoride)
Number of subjects: 7
Study 19466247 — intervention group
Group type: COMPARATOR
Intervention: Duraphat (2.26% fluorine, sodium fluoride)
Number of subjects: 7
Study 16699276 — intervention group
Group type: EXPERIMENTAL
Intervention: Cascabel chilli (3 g daily, 880 ppm capsaicin)
Number of subjects: 12
Study 16699276 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancho chilli (3 g daily, 488 ppm capsaicin)
Number of subjects: 12
Study 16699276 — intervention group
Group type: EXPERIMENTAL
Intervention: Both kinds of chilli
Number of subjects: 12
Study 15297049 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexavalent outer membrane vesicle (OMV) vaccine (HexaMen) containing six different porin A (PorAs)
Number of subjects: 0
Study 15297049 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexavalent outer membrane vesicle (OMV) vaccine (HexaMen)
Number of subjects: 0
Study 11299084 — intervention group
Group type: EXPERIMENTAL
Intervention: High trans alpha-linolenic acid diet
Number of subjects: 88
Study 11299084 — intervention group
Group type: COMPARATOR
Intervention: Low trans alpha-linolenic acid diet
Number of subjects: 88
Study 9279176 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate (0 to 14.2 mmol/kg/day)
Number of subjects: 58
Study 9279176 — intervention group
Group type: COMPARATOR
Intervention: Standard parenteral nutrition
Number of subjects: 58
Study 7867679 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrivastine 8 mg
Number of subjects: 18
Study 7867679 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrivastine 16 mg
Number of subjects: 18
Study 7867679 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrivastine 24 mg
Number of subjects: 18
Study 7867679 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrivastine 8 mg + pseudoephedrine 60 mg
Number of subjects: 18
Study 7867679 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg
Number of subjects: 18
Study 7867679 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg
Number of subjects: 18
Study 7867679 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 180 mg
Number of subjects: 18
Study 7867679 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg
Number of subjects: 18
Study 7867679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2770251 — intervention group
Group type: EXPERIMENTAL
Intervention: Elementary school social skills/peer pressure resistance curriculum
Number of subjects: 0
Study 2770251 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 779391 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine (1 mg/kg i.v.)
Number of subjects: 0
Study 779391 — intervention group
Group type: EXPERIMENTAL
Intervention: Anileridine (0.25 mg/kg)
Number of subjects: 0
Study 779391 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 0
Study 31236587 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole-resistant IA
Number of subjects: 129
Study 31236587 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole-susceptible IA
Number of subjects: 129
Study 31236587 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole-resistant IA (non-ICU)
Number of subjects: 129
Study 31236587 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole-susceptible IA (non-ICU)
Number of subjects: 129
Study 31236587 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole-resistant IA (ICU)
Number of subjects: 129
Study 31236587 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole-susceptible IA (ICU)
Number of subjects: 129
Study 28237860 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 74
Study 28237860 — intervention group
Group type: COMPARATOR
Intervention: α glucosidase inhibitor (αGI)
Number of subjects: 74
Study 24894652 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg), Trastuzumab (8 mg/kg loading dose followed by 6 mg/kg), Docetaxel (100 mg/m2 initially, later amended to 75 mg/m2) every three weeks for six cycles
Number of subjects: 26
Study 24894652 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab, Trastuzumab, and Docetaxel
Number of subjects: 26
Study 23131911 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey barrier cream
Number of subjects: 31
Study 23131911 — intervention group
Group type: COMPARATOR
Intervention: Zinc oxide ointment
Number of subjects: 31
Study 20977443 — intervention group
Group type: EXPERIMENTAL
Intervention: Video education on portable video devices
Number of subjects: 84
Study 20977443 — intervention group
Group type: COMPARATOR
Intervention: Conventional verbal instructions
Number of subjects: 84
Study 20977443 — intervention group
Group type: EXPERIMENTAL
Intervention: Video education
Number of subjects: 84
Study 18607857 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance therapy
Number of subjects: 0
Study 18607857 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study 15751004 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated warfarin (2.5 mg tablets)
Number of subjects: 18
Study 15751004 — intervention group
Group type: COMPARATOR
Intervention: Nonencapsulated warfarin (2.5 mg tablets)
Number of subjects: 18
Study 12028870 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective stenting using the heparin-coated beStent
Number of subjects: 0
Study 12028870 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 0
Study 10598553 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid administered orally at 25 mg/m2 and 125 mg/m2
Number of subjects: 0
Study 10598553 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive oral administration of folic acid every 6 hours
Number of subjects: 0
Study 10598553 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive oral administration of folic acid
Number of subjects: 0
Study 7695464 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose warfarin
Number of subjects: 10000
Study 7695464 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 10000
Study 7695464 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 10000
Study 2165860 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectinomycin (2-gm single dose)
Number of subjects: 343
Study 2165860 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole (two tablets twice daily for seven days)
Number of subjects: 343
Study 722696 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine progesterone contraceptive system
Number of subjects: 24
Study 722696 — intervention group
Group type: COMPARATOR
Intervention: Placebo systems releasing no hormone
Number of subjects: 24
Study 31150916 — intervention group
Group type: EXPERIMENTAL
Intervention: Brazil nut intake (1 Brazil nut per day, approximately 1261 μg/Se) for 2 months
Number of subjects: 54
Study 31150916 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Brazil nut intake) for 2 months
Number of subjects: 54
Study 31150916 — intervention group
Group type: COMPARATOR
Intervention: Comparison of women with MetS (n=23) vs. women without MetS (n=31)
Number of subjects: 54
Study 27726029 — intervention group
Group type: EXPERIMENTAL
Intervention: Cogstate computerized battery assessment during the first month of induction chemotherapy
Number of subjects: 34
Study 27726029 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF biomarkers (folate, homocysteine, 8-isoprostane, and myelin basic protein)
Number of subjects: 34
Study 25431345 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular tachyarrhythmias (VTA) occurring in the morning hours
Number of subjects: 1790
Study 24249817 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic combination (Bifidobacterium infantis, Streptococcus thermophilus, and Bifidobacterium lactis, 1 × 10(9) total organisms)
Number of subjects: 1099
Study 24249817 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 1099
Study 21661431 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization (TACE) before surgical resection (Group A)
Number of subjects: 72
Study 21661431 — intervention group
Group type: COMPARATOR
Intervention: Direct surgical resection of HCC (Group B)
Number of subjects: 72
Study 19628361 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk group (<=3 pts)
Number of subjects: 1166
Study 19628361 — intervention group
Group type: EXPERIMENTAL
Intervention: Med-risk group (4-7 pts)
Number of subjects: 1166
Study 19628361 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group (>=8 pts)
Number of subjects: 1166
Study 19628361 — intervention group
Group type: COMPARATOR
Intervention: Comparison to PIII derivation set
Number of subjects: 1166
Study 19628361 — intervention group
Group type: COMPARATOR
Intervention: Comparison to PIII validation set
Number of subjects: 1166
Study 19628361 — intervention group
Group type: COMPARATOR
Intervention: Comparison to retrospective multicenter validation set
Number of subjects: 1166
Study 16766321 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialised cognitively accessible interface
Number of subjects: 32
Study 16766321 — intervention group
Group type: COMPARATOR
Intervention: Standard Windows CE interface
Number of subjects: 32
Study 15574615 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraprofessional visits
Number of subjects: 735
Study 15574615 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse visits
Number of subjects: 735
Study 15574615 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 735
Study 11382657 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flavonoid (HF) diet enriched with onions and black tea
Number of subjects: 32
Study 11382657 — intervention group
Group type: COMPARATOR
Intervention: Low-flavonoid (LF) diet
Number of subjects: 32
Study 9416458 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB)
Number of subjects: 10
Study 9416458 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP)
Number of subjects: 10
Study 9416458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9416458 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 10
Study 9416458 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid
Number of subjects: 10
Study 9416458 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 10
Study 9416458 — intervention group
Group type: EXPERIMENTAL
Intervention: Losigamone (LSG)
Number of subjects: 10
Study 8297946 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate in lipid emulsion (Etomidat‐Lipuro)
Number of subjects: 232
Study 8297946 — intervention group
Group type: COMPARATOR
Intervention: Etomidate in propylene glycol (Hypnomidate)
Number of subjects: 232
Study 8297946 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 232
Study 3562890 — intervention group
Group type: EXPERIMENTAL
Intervention: one cycle of combination chemotherapy + radiation therapy + 5 cycles of combination chemotherapy
Number of subjects: 237
Study 30124758 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 147
Study 30124758 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 147
Study 27100124 — intervention group
Group type: EXPERIMENTAL
Intervention: LGB-affirmative psychotherapy (10-session individual intervention)
Number of subjects: 54
Study 24684153 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-child visits with a behavioral health provider
Number of subjects: 94
Study 24684153 — intervention group
Group type: COMPARATOR
Intervention: Standard well-child visit
Number of subjects: 94
Study 22943819 — intervention group
Group type: EXPERIMENTAL
Intervention: C.E.R.A. once every 4 weeks by subcutaneous administration
Number of subjects: 253
Study 22943819 — intervention group
Group type: COMPARATOR
Intervention: EPO 1-3 times weekly
Number of subjects: 253
Study 20551967 — intervention group
Group type: EXPERIMENTAL
Intervention: SMOFlipid fat emulsion (omega-3 fatty acids)
Number of subjects: 38
Study 20551967 — intervention group
Group type: COMPARATOR
Intervention: Standard fat emulsion (Intralipid)
Number of subjects: 38
Study 18386580 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng Injection (SFI) combined with chemotherapy
Number of subjects: 60
Study 18386580 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CTF regimen)
Number of subjects: 60
Study 15769240 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning of response verification present
Number of subjects: 0
Study 15769240 — intervention group
Group type: COMPARATOR
Intervention: No warning of response verification
Number of subjects: 0
Study 12940840 — intervention group
Group type: EXPERIMENTAL
Intervention: real-rTMS (suprathreshold 5-Hz, 2000 pulses once a day for 10 consecutive days)
Number of subjects: 36
Study 12940840 — intervention group
Group type: COMPARATOR
Intervention: sham-rTMS
Number of subjects: 36
Study 20287462 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine treatment
Number of subjects: 23
Study 8856584 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL-6 levels in patients with Crohn's disease
Number of subjects: 41
Study 8856584 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL-2R levels in patients with Crohn's disease
Number of subjects: 41
Study 8856584 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL-6 levels in moderate/severe Crohn's disease
Number of subjects: 41
Study 8856584 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL-2R levels in moderate/severe Crohn's disease
Number of subjects: 41
Study 8856584 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of IL-6 with ESR
Number of subjects: 41
Study 8856584 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of IL-2R with ESR
Number of subjects: 41
Study 1503928 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with common ALL, WBC 10-50 x 10(9) 1-1, aged 18 months or older
Number of subjects: 0
Study 1503928 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort of children under 2 years
Number of subjects: 0
Study 1503928 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with WBC under 10 x 10(9) 1-1
Number of subjects: 0
Study 6517248 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 0
Study 6517248 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrronium
Number of subjects: 0